Search

Displaying results 2871 - 2880 of 10000 in total
  1. Drug

    Evinacumab

    go.drugbank.com/drugs/DB15354
    ApprovedInvestigational

    [A229273] Loss-of-function mutations in _ANGPTL3_ have been noted to result in hypolipidemia and subsequent reductions in cardiovascular risk, whereas increases in function appear to be associated with … The ANGPTL family of proteins serve a number of physiologic functions - including involvement in the regulation of lipid metabolism - which have made them desirable therapeutic targets in recent years.

  2. Drug

    Azficel-T

    go.drugbank.com/drugs/DB11051
    ApprovedWithdrawn

    Expanded cells are then suspended in a cell medium. … Azficel-T is an autologous cellular product composed of fibroblasts indicated for improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults.

  3. Drug

    Deutivacaftor

    go.drugbank.com/drugs/DB15141
    ApprovedInvestigational

    [L52275,A179677] Deutivacaftor was first approved by the US FDA in December 2024 in combination with two CFTR correctors - [tezacaftor] and [vanzacaftor] - for the treatment of patients with responsive … It is used alongside CFTR correctors to increase the quantity and function of CFTR at the cell surface in patients with cystic fibrosis.

  4. Drug

    Clove oil

    go.drugbank.com/drugs/DB11338
    ApprovedNutraceutical

    Clove is native of Indonesia but is now cultured in several parts of the world, including Brazil in the state of _Bahia_. … Traditionally, it has been used as a flavouring spice in foods, or as a fragrance. It is also found in topical analgesics. Clove oil has shown to exert some antimicrobial activities.

  5. Drug

    Alferminogene tadenovec

    go.drugbank.com/drugs/DB05306
    Investigational

    Alferminogene tadenovec, Cardium’s lead product candidate, is being developed for the potential treatment of myocardial ischemia that gives rise to angina symptoms associated with coronary heart disease. Alferminogene tadenovec represent...

  6. Drug

    Maraviroc

    go.drugbank.com/drugs/DB04835
    ApprovedInvestigational

    It was approved for use by the FDA in August, 2007.

  7. Drug

    Recombinant stabilized RSV A prefusion F antigen

    go.drugbank.com/drugs/DB18713
    ApprovedInvestigational

    [L49555] Abrysvo was approved for the same indications in the EU in August 2023[L49565] and Canada in December 2023. … of an adjuvant.

  8. Drug

    Ethyl macadamiate

    go.drugbank.com/drugs/DB11243
    Approved

    It is a non-volatile ester of ethyl alcohol and the fatty acids. … Ethyl macadamiate is used in cosmetics and personal care products such as sunscreen, hair care products and skin care products as an emollient and skin conditioning agent.

  9. Drug

    DDP-200

    go.drugbank.com/drugs/DB05919
    Experimental

    DDP200 is developed by Dynogen for the treatment of non-incontinent form of overactive bladder (OAB) with particular focus on both male and female patients with urinary frequency, urinary urgency and nocturia

  10. Drug

    Enmetazobactam

    go.drugbank.com/drugs/DB18716
    ApprovedInvestigational

    [A263276] The combination product of enmetazobactam and [cefepime] was first approved by the FDA on February 23, 2024, for the treatment of complicated urinary tract infections. … [A263266] Because ESBL enzymes can hydrolyze important antibiotics such as penicillins, broad-spectrum cephalosporins and monobactams, ESBL-producing bacteria poses challenges in the treatment of serious